News | November 08, 2024
Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Granules now has a total of 67 ANDA approvals from the USFDA
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Subscribe To Our Newsletter & Stay Updated
